Current Email Edition Sponsor:

Anavex Completes Successful Preclinical Studies On Lead Alzheimer's Drug Candidate

Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announced the successful completion of preclinical studies (in-vitro and in-vivo in mice) on ANAVEX 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease.

Read the Entire News Item:

Anavex Completes Successful Preclinical Studies On Lead Alzheimer's Drug Candidate

Source: Medical News Today Alzheimer's

Page Options:

Email | Post a Comment | Bookmark/Share

Permalink:
http://TheDiabeticNews.com/content/feeds/2008/9/3/829

Browse Related Newsfeed Departments:


Syndication

You can syndicate content from The Diabetic News website for use on your own website or have it delivered to an aggregator or feed reader.
Main RSS Feed | More RSS Options


Information provided is for entertainment purposes only and is not a substitute for professional medical advice. Only your healthcare provider should diagnose your healthcare problems and prescribe treatment. All visitors are required to read our complete website Terms of Use before using this website and are invited to read our privacy policy. Copyright © CAPCO Marketing. All rights reserved.